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Abstract Stable complexes of cationic liposomes with plasmid 
DNA were prepared by (1) including a small amount of 
poly(ethylene glycol)-phospholipid conjugate or (2) condensing 
the DNA with polyamines prior to the formation of liposome-
plasmid complexes. These preparations were stable for months at 
4°C and gave reproducible high transfection activity for in vivo 
gene delivery after intravenous injection in mice. Under these 
conditions, the expression of marker gene (luciferase) was 
primarily in the lungs (reaching values up to 3 ng expression 
per mg tissue protein), but also in other tissues to a lesser extent. 
Non-stabilized formulations lost all their transfection activity in 
4 days. In these formulations cholesterol, not dioleoylphos-
phatidylethanolamine, was the helper lipid effective for sustain-
ing high transfection activity in vivo. These new developments in 
formulation technology should enhance the potential for 
liposome-mediated gene therapy. 
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1. Introduction 
Liposomes which consist of amphiphilic cationic molecules 
have been considered as a potential non-viral vector for gene 
delivery (reviewed in [1-5]). In theory, the positively charged 
liposomes can complex to the negatively charged plasmids via 
electrostatic interactions. The plasmid-liposome complexes 
have several advantages as gene transfer vectors. Unlike viral 
vectors, plasmid-liposome complexes can be used to transfer 
expression cassettes of essentially unlimited size. Since the 
complexes lack proteins, they may evoke fewer immunogenic 
and inflammatory responses. Moreover, they cannot replicate 
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Abbreviations: Choi, cholesterol; DC-chol, 3P-[7V-(7V',iV'-dimethyl-
aminoethane)carbamoyl]cholesterol; DDAB, dimethyldioctadecylam-
monium bromide; DMEPC, dimyristoylglycero-3-ethylphos-
phocholine; DODAP, dioleoyl-3-dimethylammonium propane; 
DOEPC, dioleoylglycero-3-ethylphosphocholine; DOGS, iV,/V-diocta-
decylamidoglycylspermine; DOPE, dioleoylphosphatidylethanol-
amine; DOTAP, dioleoyl-3-trimethylammonium propane; DOTMA, 
Ar-[2,3-(dioleyloxy)propyl]-JV,./V~,./V-trirnethylammonium bromide; 
DSPE, distearoylphosphatidylethanolamine; DTT, dithiothreitol; 
ESPM, ethyl sphingomyelin (egg); LYSPE, lysinyl dipalmiltoylphos-
phatidylethanolamine; MMCE, myristylmyristoyl carnitine ester; 
PEG-PE, iV-[co-methoxypoly(oxyethylene)-a-oxycarbonyl]-DSPE; 
POEPC, palmitoyloleoylglycero-3-ethylphosphocholine. 
or recombine to form an infectious agent and have low inte-
gration frequency. 
There are a number of publications which demonstrate con-
vincingly that cationic liposomes can mediate gene delivery by 
showing detectable expression of a reporter gene in culture 
cells in vitro [6-8]. Because liposome-plasmid complexes are 
not as efficient as viral vectors for achieving successful gene 
transfer, much effort has been devoted in finding 'better' cat-
ionic lipids for increasing the transfection efficiency [3-5]. Lip-
osome-plasmid complexes are presently recognized with en-
thusiasm by researchers at both academic institutions and 
pharmaceutical industries as a potentially useful tool for 
gene therapy, although the mechanism of liposome-mediated 
gene transfection is still not well understood. Few studies have 
begun to deal with the structure-function relationship of the 
liposome-plasmid complex [5,9], but to date no clear correla-
tion between complex structure and transfection activity has 
been shown. 
During the last few years, several groups have reported on 
the use of cationic liposomes for in vivo transfection both in 
animals, and in humans (reviewed in [5,10-13]). Despite con-
siderable promise, the technical problems for preparation of 
stable complexes have not been addressed as yet. Unlike viral 
vector preparations, liposome-plasmid complexes are not 
stable in terms of particle size [3-5]. It has been difficult to 
obtain homogeneous liposome-plasmid complexes with size 
distribution suitable for systemic injection, and metastable 
preparations of liposome-plasmid complexes were used in 
most published studies. Frequently, these complexes were 
used within a short period of time ranging from 30 min to 
a few hours. In recent clinical trials using cationic lipids as a 
carrier for DNA delivery, the two components were mixed at 
the bed-side and used immediately [5]. The structural instabil-
ity along with the loss of transfection activity of liposome-
DNA complex with time have been challenges for the future 
development of liposome-mediated gene therapy. Develop-
ment of stable, well-defined formulations is critically needed 
for facilitating efforts to correlate the structural parameters of 
liposome-DNA complexes to their transfection activity in 
vivo. 
Here, we report a systematic study describing the formula-
tion of stable plasmid-liposome complexes which maintain 
high transfection activity after intravenous injection in mice 
using luciferase as a reporter gene expression. We identified 
cholesterol, not dioleoylphosphatidylethanolamine (DOPE) as 
an effective 'helper' lipid in dimethyldioctadecylammonium 
bromide (DDAB) liposomes for in vivo gene delivery. In 
vivo transfection activity of these stable formulations was 
maintained in storage at 4°C for up to 2 months. 
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2. Materials and methods 
2.1. Lipids and other reagents 
DOPE was purchased from Avanti (Alabaster, AL). Highly purified 
cholesterol was obtained from Calbiochem (San Diego, CA). DDAB 
was purchased from Sigma (St. Louis, MO). DDAB was recrystallized 
once from acetone-methanol solution. D-Luciferin was obtained from 
Boehringer Mannheim. PEG-PE was a gift from Sequus Pharmaceu-
ticals (Menlo Park, CA). DC-Choi, MMCE and DOGS were obtained 
from the UCSF Gene Transfer Vehicle Core of Gene Therapy Center. 
ESPM, DOTAP, POEPC, DOEPC, DMEPC and DODAP were gifts 
from Avanti (Alabaster, AL). Chloroform solution of each lipid was 
stored under argon in sealed ampules at —40°C. Other reagents of the 
highest possible grade were purchased and used without further pur-
ification. 
2.2. Preparation of liposomes 
Small cationic liposomes were prepared in 5% (w/v) dextrose solu-
tion in the following fashion. DDAB or other cationic lipids in 
chloroform was mixed with DOPE or/and cholesterol in the desired 
molar ratio, and the solvent was removed slowly under reduced pres-
sure at 50°C on a rotary evaporator. The dry lipid film was hydrated 
with 5% dextrose solution prewarmed to 50°C and the container was 
sealed under argon. The hydrated lipid suspension was sonicated in a 
bath sonicator (Lab Supplies, Hicksville, NY) for 5-10 min at 50°C. 
The final concentration of liposomes was 5 mM cationic lipid and the 
size of liposomes was measured by dynamic light scattering to be 
195 ±65 nm. Sonicated liposomes were stored under argon at 4°C 
until use. 
2.3. Luciferase reporter system 
Plasmid, pCMV/IVS-luc+, was constructed as follows. A fragment 
containing the CMV promoter and synthetic IgE intron was excised 
from pBGt2.CAT using Spel and Hindlll and cloned into pBSIIKS+. 
The cDNA encoding the modified firefly luciferase (luc+) including 
SV40 late poly(A) signal was cut from the pGL3-Basic Vector (Pro-
mega) with Hindlll and Sail and was put into the pBS-CMV-IVS 
clone downstream of the splice. Plasmids were purified using alkaline 
lysis procedures adopted and devised by Qiagen Corp. (Chatsworth, 
CA). Plasmid purity was measured by the ratio of absorbance at 260 
nm vs. 280 nm, and purified plasmids were stored in buffer containing 
10 mM Tris-Cl and 1 mM EDTA at pH 8.0 at concentrations of 1-2 
mg/ml. 
2.4. Preparation of transfection complexes 
Prior to the transfection experiments, the optimal DNA/liposome 
ratio for forming complexes which were not large aggregates was 
determined by mixing a fixed amount of plasmid with various 
amounts of liposomes. In general, the transfection complexes were 
formed by pipetting plasmid into a liposome suspension of equal 
volume and mixing rapidly. The final DNA concentration of the com-
plexes was 200 μg/ml for in vivo studies and 10 μg/ml for in vitro 
studies. Routinely, liposomes containing 8-12 nmol of DDAB could 
complex with 1 μg plasmid without forming visible large aggregates. 
Such complexes have excess positive charge, but still tend to aggregate 
with time during storage at 4°C and lose transfection activity in 4 
days. For in vitro experiments, which called for much dilute com-
plexes, DNA-liposome complexes at 5-12 nmol DDAB per μg 
DNA could be formed. To keep the plasmid-liposome complexes 
from forming large aggregates and losing transfecting activity with 
time, two approaches were taken: (1) incorporating a small amount 
of PEG-PE (from 0.5 to 2% of cationic lipid) by addition to the 
DNA-liposome complexes within a few minutes after their prepara-
tion; (2) condensing plasmid with polyamines (e.g. 0.5 nmol of sper-
midine per μg DNA) prior to mixing with liposomes. The optimal 
amount of polyamines was determined by titrating polyamines to 
DNA before forming large aggregates. The size of these complexes 
was estimated by dynamic light scattering to be in the range of 
410 ±150 nm. 
2.5. Assay of reporter gene expression 
Purified luciferase was purchased from Boehringer Mannheim as a 
standard for calibrating the luminometer and constructing a control 
standard for the relative specific activity of luciferase. Reporter gene 
expression in a tissue extract was presented in nanogram quantities by 
converting relative light units measured from a luminometer into 
weight units according to a standard curve. Luciferase expressed in 
cells or tissues was extracted with cell lysis solution. Effective lysis 
buffer consisted of 0.1 M potassium phosphate buffer at pH 7.8, 1% 
Triton X-100, 1 mM DTT and 2 mM EDTA. 
Female CD1 mice (4-6 weeks old, weighing approx. 25 g) were 
obtained from Charles River Laboratory. Mice received liposome-
plasmid complexes by tail vein injection and were killed 24 h later. 
The anesthetized animals were perfused with cold phosphate-buffered 
saline (PBS) via heart puncture. Each tissue was dissected and washed 
in PBS, and then homogenized in 6 ml round-bottomed culture tubes 
containing 500 μΐ of lysis buffer. The samples were kept at room 
temperature for 20 min with occasional mixing. The homogenized 
samples were centrifuged for 10 min at 3000 rpm in an Eppendorf 
centrifuge. Luciferase activity of each tissue was measured by mixing 
100 μΐ of the reconstituted luciferase substrate (Promega, Madison, 
WI) with 20 μΐ of the supernatant of tissue homogenate in the injec-
tion system of a luminometer. Peak light emission was measured for 
10 s at 20°C. Relative light units of each sample were converted to the 
amount of luciferase in the tissue extract by comparing with a stand-
ard curve which was established for each set of experiments. The 
protein content of the extract was determined using protein assay 
kits (BioRad, Richmond, CA). Background was the count of lysis 
buffer in tissues of mice without treatment. We have obtained con-
sistent negative controls of tissue samples from mice that were treated 
with liposomes only or with complexes with β-gal DNA. The lucifer-
ase activity of these tissues measured was at the same level as lysis 
buffer analysis, i.e. 200-300 RLU. After background subtraction, the 
detection limit of our luminometer was linear on a log scale from 
2X102 to 9X106 RLU, which corresponded to 3X10"5 ng up to 
3 ng luciferase. 
SK-BR-3 cells [14] were cultured in McCoy's 5 A medium supple-
mented with 10% heat-inactivated bovine calf serum and in 5% CO2. 
SK-BR-3 cells in monolayer culture were plated at 50000 cells per 
well in 12-well plates and incubated overnight. Each well received 0.5-
1 μg of pCMV/IVS-luc+ within 20 min of complex formation. Cells 
were harvested after 24 h of incubation with complexes at 37°C. 
Luciferase activity in cells was determined as described above. 
3. Results and discussion 
The use of cationic liposomes for in vitro gene transfer has 
become widespread since Feigner et al. [6] reported their early 
study. It was established later [8] that D O P E is by far the 
most efficient helper lipid for in vitro gene transfection and 
this has been confirmed by several laboratories [15,16]. It has 
been suggested, on the basis of in vitro studies, that D O P E 
may facilitate cytoplasmic delivery via membrane fusion once 
positively charged DNA-liposome complexes are bound to the 
cell membrane [16]. Even though Friend et al. [17] did not 
obtain any morphological evidence that the D O T M A / D O P E 
liposome-plasmid D N A complexes fuse directly with the plas-
ma membrane, they do not exclude the possibility of fusion 
events. They suggested that the complexes are endocytosed 
and the cationic lipids disrupt the endosomal/lysosomal mem-
branes and then facilitate escape of the D N A complexes into 
the cytoplasm and eventually into the nucleus. 
Contrary to most expectations, the helper role of D O P E 
established from in vitro studies is not evident for in vivo 
gene delivery following i.v. injection of the complexes. We 
found that when D O P E was included in D D A B cationic lipo-
somes, in vivo gene transfection was inhibited. This D O P E -
dependent inhibition is shown in Fig. 1. Cholesterol, not 
D O P E , was found to be effective as helper lipid for in vivo 
gene delivery. There was a 10-fold reduction in luciferase ex-
pression in mouse lungs when half of the cholesterol was 
replaced with D O P E . Our in vivo results of D D A B and other 
cationic liposomes are not consistent with the general assump-
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tion that DOPE is a suitable helper lipid. On the contrary, 
DOPE in cationic liposome-plasmid complexes attenuates the 
in vivo transfection to such a great degree that we consider 
DOPE as an inhibitory agent in formulations for in vivo gene 
delivery. Cholesterol has been chosen for in vivo studies in 
recent published reports [11,12] in which the authors do not 
elaborate on how and why they selected different helper lipids 
for their experimental designs, i.e. DOPE for in vitro and 
cholesterol for in vivo studies. Stabilization of anionic and 
neutral liposomes in blood by cholesterol has been known 
for a long time [18]. It is therefore obvious that for systemic 
gene delivery, one has to consider the stability of liposome-
DNA complexes in blood, various components of which are 
known to react with macromolecular complexes. In fact, our 
preliminary study of various formulations of plasmid-lipo-
some complexes using freeze-fracture electron microscopy 
has shown that the cholesterol-containing complexes were 
structurally more stable than the DOPE-containing complexes 
in the presence of serum. In 50% serum, DOPE-containing 
complexes form very large multilamellar and hexagonal lipid 
structures, while cholesterol-containing complexes maintain 
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Fig. 1. Role of neutral lipid in gene delivery: cholesterol vs. DOPE. 
Three liposome formulations were tested for gene delivery to both 
culture cells (SKBR-3, human breast cancer cell) and mice (CD1, 
female, 20-25 g). 1, DDAB/Chol (1:1); 2, DDAB/Chol/DOPE 
(1:0.5:0.5); 3, DDAB/DOPE (1:1); 4, DDAB alone. (A) Cell trans-
fection: SKBR-3 cells were plated at 50000 cells per well in 12-well 
plates and incubated overnight. Each well received 1 μg of P-CMV/ 
IVS-Luc+ plasmid which was complexed with liposomes at 8 nmol 
of DDAB. Cells were harvested after 24 h incubation with com-
plexes at 37°C. Values presented are mean from 2 wells. Values 
ranged within 10-30% of mean. (B) In vivo transfection in mice 
(lungs): mice received via tail vein injection 60 μg of P-CMV/IVS-
Luc+ plasmid which was complexed with liposomes at 8 nmol 
DDAB per μg DNA ratio. Values presented are mean from 2 mice. 
Values ranged within 20-25% of mean. Since it required more con-
centrated complexes for i.v. injection, DDAB alone did not form 
suitable complexes for this study. 
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Fig. 2. Reporter gene expression in mouse tissue extracts. Mice re-
ceived (via tail vein injection) 60 μg of P-CMV/IVS-Luc+ plasmid, 
which was complexed with DDAB/Chol (1:1) liposomes at 8 nmol 
DDAB per μg DNA ratio (without spermidine). Artery was for 
large blood vessels we could harvest. Values presented were mean 
from 3 mice. 
small liposomal structures showing simple aggregation of li-
posomes by plasmid. Morphological observations of the struc-
tural characteristics of different formulations of liposome-
plasmid complexes will be published separately. 
Using DDAB/Chol liposome-DNA complexes (8 nmol 
DDAB^g DNA) for in vivo transfection experiments, we 
have found that detectable luciferase expression in the lung 
of 25 g mouse required a DNA dose ranging from 30 to 60 
μg. Routinely, 40-60 μg plasmid DNA per mouse gave con-
sistent gene expression. The amount of DDAB usually asso-
ciated with 80 μg DNA (or more) per mouse was found to be 
too toxic to the animal. The expression of luciferase in various 
tissues is shown in Fig. 2. As observed before [10-12], max-
imal expression was found in lung tissue. For 60 μg plasmid 
injected, 1-2 ng luciferase per mg tissue protein was routinely 
obtained. Fig. 3 shows the duration of reporter gene expres-
sion in lung tissue. Expression of luciferase decreased rapidly 
during the first 3 days and reached undetectable levels in 
1 week. Zhu et al. [10] reported that following i.v. injection 
of DOTMA/DOPE (1 :l)-plasmid complexes into adult mice, 
the expression of the reporter gene (CAT) is widespread 
among various tissues and the maximum expression is from 
complexes with a ratio of 1 μg plasmid to 8 nmol total lipids. 
However, at this ratio (corresponding to 1 μg plasmid to 
4 nmol cationic lipid), DDAB/Chol liposome-plasmid com-
plexes tended to aggregate and did not produce measurable 
gene expression in our investigation. 
Since different reporter genes have been used among differ-
ent laboratories, it has been difficult to attribute the variations 
in the efficiency of in vivo gene delivery to changes in the 
formulation of liposomes. For a direct comparison of the 
results in the literature, we have converted the relative light 
units of luciferase activity measured from a luminometer to a 
standard of purified luciferase. By doing so, we have found 
that the peak transfection activity of DDAB/Chol formula-
tions was 3 orders of magnitude higher than values reported 
recently in comparable experiments [13]. Given that same re-
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Fig. 3. Duration of reporter gene expression in mouse lungs. Each 
animal received 40 μg of P-CMV/IVS-Luc+ plasmid which was 
complexed with DDAB/Chol (1:1) liposomes at 8 nmol DDAB per 
μg DNA ratio. 
porter gene along with the same promoter in the experimental 
design, the difference in expression may reflect the selection of 
liposome formulation. In fact, DDAB/Chol was one of the 
most efficient gene delivery vehicles among many formulations 
from 18 different cationic lipids which we screened recently. 
Preliminary results of expression in mouse lung following i.v. 
injection indicated that DOTMA/Chol, DOTAP/Chol, 
MMCE/Chol and ESPM/Chol gave 10-100% transfection ac-
tivity of DDAB/Chol, DOGS/Chol, POEPC/Chol, LYSPE/ 
DOPE and DC-Chol/DOPE gave 1-10% of DDAB/Chol. 
DOEPC/Chol, DMEPC/Chol, DODAP/Chol and DDAB/ 
DOPE did not give any measurable activity. 
The relationship between structural stability and transfec-
tion activity of liposome-DNA complexes has not been de-
tailed in the published reports so far. We have established 
screening procedures to avoid large aggregates of plasmid-li-
posome complexes by changing the ratio of DNA to lipid 
from net negatively charged to positively charged. DNA-lipo-
some complexes of each particular cationic lipid at various 
ratios of DNA/lipid were prepared and the resulting stable 
and metastable formulations were used for in vivo transfec-
tion. Complexes which contained 8-12 nmol of cationic lipid 
per μg DNA were found to have the highest in vivo transfec-
tion activity. However, the transfection activity of these com-
plexes decreased with time. Without modifying the procedures 
for forming the DNA-liposomes complexes, there was a visi-
ble aggregation within a few days, and the transfection activ-
ity decreased by more than 1000-fold to almost background 
levels after 1 month storage at 4°C (Fig. 4). Therefore, we 
undertook to formulate stabilized DNA-liposome complexes 
which could maintain high in vivo transfection activity during 
storage. 
It has been established recently that PEG-PE incorporation 
in liposomes produces steric stabilization resulting in longer 
circulation times in blood [19,20]. We have found that adding 
PEG-PE (1% of cationic lipid) into the freshly formed plas-
mid-liposome complexes could prevent the complexes from 
aggregating during storage. Incorporation of PEG-PE into 
the complexes is evident in view of the dose-related inhibition 
of the transfection activity with increasing percentage of PEG-
PE: addition of 0.5% PEG-PE reduces activity down to 60%, 
1% down to 40%o and 2% down to 10% of original luciferase 
activity in lungs. However, storage of the complexes contain-
ing PEG-PE at 4°C slowly restored the original activity as 
shown in Fig. 4. Addition of free PEG 2000 in solution of 
up to 3 mM to comparable complexes did not affect the 
transfection activity. The mechanistic aspects of the inhibition 
effect on transfection by PEG-PE, as well as the recovery of 
the activity following storage at low temperature, are not 
known at the present time. Further structural studies on these 
complexes are warranted. 
Small polycationic molecules are known to condense DNA 
via electrostatic charge-charge interactions [21]. The pretreat-
ment of plasmid DNA with polyamines can therefore reduce 
the number of charge sites for complexing with cationic lipo-
somes. The plasmid-liposome complexes formed with such 
pretreatment were stable at a lower ratio of lipid to DNA 
without aggregation. Fig. 4 shows the level of in vivo trans-
fection activity of such preparation, and its fate during stor-
age. Again, we found an increase in transfection activity in 
aged polyamine-treated liposome-DNA complexes, when 
compared to that of the samples which were not pretreated 
with polyamines and used immediately after complexes were 
formed. 
We have determined the transfection activity of some sta-
bilized formulations up to 2 months in storage. The activity of 
such formulations at that time point did not decrease and was 
practically the same as that of a 1-month-old sample. A dif-
ferent approach to obtain stable cationic lipid/DNA com-
plexes by complexing plasmid with lipid in lipid-detergent 
micelles was published recently [22]. However, only 30% of 
the transfection efficiency was maintained by such complexes 
in 15% serum for in vitro, and no in vivo results were re-
ported. 
We conclude that several of the cationic liposome-plasmid 
complexes described in this report are stable and can give 
consistent in vivo transfection activity (ranging from 0.5 to 
3 ng luciferase per mg tissue protein) even after long storage 
at 4°C. Formulations containing cholesterol as the helper lipid 
generate much higher in vivo transfection efficiency. Stabiliz-
ing the complex structure by PEG-PE maintains the complex 
activity in storage and may prolong the circulation time in 
blood for targeting to specific tissues. Condensing the DNA 
Fig. 4. Gene delivery in mouse lung by various stabilized complexes. 
Each mouse received 60 μg of PCMV/IVS-Luc+ which was com-
plexed with DDAB/Chol (1:1) liposomes at 8 nmol DDAB^g 
DNA ratio. Values presented are mean from 3 mice. (Stippled bars) 
Freshly made complexes; (filled bars) 1-month-old samples. 1, no 
stabilizing agent was added; 2, PEG-PE was added at 1% of cation-
ic lipid to the formed complexes; 3, spermidine (0.5 nmol per μg 
DNA) was added to the plasmid prior to the formation of com-
plexes. 
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with polyamines before lipid complexation stabilizes the com-
plexes in storage and maintains their activity in vivo. Our 
methodical approach for producing stable formulations of 
DNA-liposome complexes exhibiting high transfection activity 
in vivo should confer advantages for establishing pharmaceu-
tically acceptable preparations, and could therefore facilitate 
liposome-based gene therapy. 
Acknowledgements: We thank Drs. Dmitri Kirpotin and Olivier 
Meyer for their comments regarding the preparation of this manu-
script. This research was partially supported by Bayer Corporation 
References 
[1] Crystal, R.G. (1995) Science 270, 404-410. 
[2] Blaese, M., Blankenstein, T., Brenner, M., Cohen-Haguenauer, 
O., Gansbacher, B., Russell, S., Sorrentino, B. and Velu, T. 
(1995) Cancer Gene Ther. 2, 291-297. 
[3] Behr, J.-P. (1994) Bioconj. Chem. 5, 382-389. 
[4] Remy, J.-S., Sirlin, C , Vierling, P. and Behr, J.-P. (1994) Bio-
conj. Chem. 5, 647-654. 
[5] Gao, X. and Huang, L. (1995) Gene Ther. 2, 710-722. 
[6] Feigner, P.L., Gadek, T.R., Holm, M., Roman, R., Chan, H.S., 
Wenz, M., Northrop, J.P., Ringold, M. and Danielsen, H. (1987) 
Proc. Natl. Acad. Sci. USA 84, 7413-7417. 
[7] Loeffler, J.-P. and Behr, J.-P. (1993) Methods Enzymol. 217, 
599-618. 
[8] Feigner, J.H., Kumar, R., Sridhar, C.N., Wheeler, C.J., Tsai, 
Y.J., Border, R., Ramsay, P., Martin, M. and Feigner, P.L. 
(1994) J. Biol. Chem. 269, 2550-2561. 
[9] Xu, Y. and Szoka, F.C. (1996) Biochemistry 35, 5616-5623. 
[10] Zhu, N., Liggitt, D., Liu, Y. and Debs, R. (1993) Science 261, 
209-211. 
[11] Liu, Y., Liggitt, D., Zhong, W., Tu, G., Gaensler, K. and Debs, 
R. (1995) J. Biol. Chem. 270, 24864-24870. 
[12] Solodin, I., Brown, C.S., Bruno, M.S., Chow, C.-Y., Jang, E.-H., 
Debs, R.J. and Heath, T.D. (1995) Biochemistry 34, 13537-
13544. 
[13] Thierry, A.R., Lunardi-Iskandar, Y., Bryant, J.L. Robinovich, 
P., Gallo, R.C. and Mahan, L.C. (1995) Proc. Natl. Acad. Sci. 
USA 92, 9742-9746. 
[14] Park, J.W., Hong, K., Carter, P., Asgari, H., Guo, L.Y., Keller, 
G.A., Wirth, C , Halaby, R., Kotts, C , Wood, W.I., Papahadjo-
poulos, D. and Benz, C.C. (1995) Proc. Natl. Acad. Sci. USA 92, 
1327-1331. 
[15] Farhood, H., Xiang, G., Son, K.-H., Yang, Y.-Y., Lazo, J.S., 
Barsoum, J., Bottega, R., Epand, R.M. and Huang, L. (1994) in: 
Gene Therapy for Neoplastic Diseases (Huber B.E. and Lazo, 
J.S. eds.) pp. 23-55, N.Y. Acad. Sci. 
[16] Zhou, X. and Huang, L. (1994) Biochim. Biophys. Acta 1189, 
195-203. 
[17] Friend, D.S., Papahadjopoulos, D. and Debs, R.J. (1996) Bio-
chim. Biophys. Acta 1278, 41-50. 
[18] Mayhew, E., Rustum, Y., Szoka, F. and Papahadjopoulos, D. 
(1979) Cancer Treat. Rep. 63, 1923-1928. 
[19] Allen, T.M., Hansen C , Martin, F., Redemann, C. and Yau-
Yong, A. (1991) Biochim. Biophys. Acta, 1066, 29-36. 
[20] Papahadjopoulos, D., Allen, T., Gabizon, A., Mayhew, E., Mat-
thay, K., Huang, K., Lee, K.-D., Woodle, M.C., Lasic, D.D., 
Redemann, C. and Martin, F.J. (1991) Proc. Natl. Acad. Sci. 
USA 88, 11460-11464. 
[21] Plum, G.E., Arscott, P.G. and Bloomfield, V.A (1990) Biopoly-
mers 30, 631-643. 
[22] Holland, H.E.J., Shephard, L. and Sullivan, S.M. (1996) Proc. 
Natl. Acad. Sci. USA 93, 7305-7309. 
